ImCheck ex-CEO Pierre d’Epenoux talks Fundraising, France and Oncology’s Next Wave | E60
After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the...
![CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]](https://flot.bio/wp-content/uploads/2026/06/Website-Thumbnail-PathoQuest-1080x648.avif)
CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored]
Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for...
Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58
When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US...
The Biotech Equity Gap: Why Curie.Bio is Re-Writing the Founder Playbook
In the high-stakes world of drug discovery, a “brilliant idea” is often described as being...
Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57
We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that...
How Europe could have more Biotech Champions like Argenx
For decades, the narrative of European biotech has been one of “innovation flight”: brilliant science...
Why the antimicrobial resistance crisis is bigger than cancer and how Immunethep is thinking differently
We’ve been hearing about the Antimicrobial Resistance (AMR) crisis for over a decade. Yet, according...
Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56
Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far....
![Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]](https://flot.bio/wp-content/uploads/2026/04/Website-Thumbnail-IMMUNOTHEP-1080x648.avif)
Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored]
Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup...
Biopharma family succession: Bial CEO António Portela’s strategy
In the high-stakes world of pharmaceutical innovation, few stories are as compelling as those of...
Never Miss a New Episode 💌
Trusted by 2500+ biopharma professionals from top companies like argenx, Roche, and Forbion. No spam, no noise.
Watch & Subscribe
